OTC market in CIS countries Russia, Ukraine and Kazakhstan. Comparative analysis and development forecasts for

Similar documents
OTC market in Russia Development forecasts for

OTC market in CIS countries Comparative analysis and development forecasts for

OTC market in the Czech Republic Development forecasts for

OTC market in Central and Eastern Europe 2008 Comparative analysis and development forecasts for

Non-pharmacy OTC market in Poland 2008

Railway. construction sector in Poland 2012 Development forecasts for Publication date: Q Language: Polish, English

FREE ARTICLE. Russian pharmaceutical market overview. Source: Pharma Poland News

Construction sector in Kazakhstan 2008 Development forecasts for Publication date: June 2008 Language: English

INVESTMENT FUNDS AND ASSET MANAGEMENT MARKET IN POLAND,

INVESTMENT FUNDS AND ASSET MANAGEMENT MARKET IN POLAND,

2016 Results Summary. Press Conference, Warsaw, 16 th March 2017

2016 Results Summary. Warsaw, 16 th March 2017

Long-Term Financing of Life Sciences Sector in Emerging Markets. February 2012

For personal use only

FOR IMMEDIATE RELEASE 19 March 2010 A&D PHARMA HOLDINGS N.V. UNAUDITED FINANCIAL STATEMENTS FOR THE 12 MONTHS ENDED 31 DECEMBER 2009

Erste Financial Services GmbH (EFS)

Bank Austria with first-half profit of over EUR 1 billion

SOPHARMA GROUP PRESENTATION. Who we are

Independent thinking ASIA-PACIFIC. quickstart guide. Leading provider of news and data on the distressed debt and leveraged finance markets.

Advantages of partnership with private equity investors. October 2012

PRESS CONFERENCE / ANALYST MEETING: TODAY, WEDNESDAY 26 AUGUST 2015 START: LOCATION: Hotel Casa 400 (Eerste Ringdijk 4, AMSTERDAM)

Investment Funds and Asset Management in Poland,

Economic connectivity in European conflict regions - The case of Transnistria -

2008 Results Revenues of $296.9 million EBITDA of $55.4 million Net Loss from continuing operations of $-24.8 million

GLOBAL TRANSACTION BANKING

PHARMACEUTICAL CHEMICAL COSMETICAL INDUSTRY ANNUAL REPORT ON THE PERFORMANCE OF ALKALOID AD SKOPJE FOR THE PERIOD JANUARY - DECEMBER 2011

ENTRY INFORMATION PACK

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire

Podravka Group business results. for period

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements. Biogen Methodology Note

Your reliable International Banking Service provider

Equity Funds Portfolio Update Data as of December 2017

Sigma Pharmaceuticals Limited

Overcoming borders. In thoughts and actions.

RBC Investor Conference

FDI in Central, East and Southeast Europe: Recovery amid Stabilising Economic Growth

ESTONIA, LATVIA, LITHUANIA - BANKING MARKET IN THE BALTICS CEE BANKING BRIEF

Bank Austria posts profit despite substantial goodwill impairment no need for capital measures thanks to strong capital base

E X P O R T P A R T N E R S H I P I N V E S T I M E N T S

ELKO GROUP AS. Unaudited Consolidated Financial Statements For 6 months ended 30 June 2016

Business Plan FEBRUARY 2013

PICPA DUBAI VAT WORKSHOP Dusit Thani Dubai 10 th November 2017

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements. Biogen Methodology Note

Content. MUTUAL FUNDS MONTHLY REVIEW 2013 July. New Europe TOP20 Subfund 1. Russia TOP20 Subfund 2. Global Flexible Subfund 3

Ukraine FDI report 2011

EBRD Communications Sector Assessment Conference. Activities of the TMT Team. 29 May 2009 Tbilisi

HSBC Trade Connections: Trade Forecast Quarterly Update October 2011

SHPA Response to Consultation on the Community Service Obligation (CSO) Funding Pool Obligations (2018)

Prescription medicines trends: an overview and perspective on two therapy areas

Medicines for Europe (MFE) HCP/HCO/PO Disclosure Transparency Requirements. Samsung Bioepis Methodology Note

Q3 FY09 Results Update

Yandex Announces Fourth Quarter and Full-Year 2013 Financial Results

PHARMACEUTICAL CHEMICAL COSMETICAL INDUSTRY CONSOLIDATED ANNUAL REPORT ON THE PERFORMANCE OF ALKALOID AD SKOPJE FOR THE PERIOD JANUARY - DECEMBER 2010

The past year s key changes in the regulation of the pharma industry

Methodological Note. - Merck Oy Finland -

P R E S S R E L E A S E Vienna, 17 March 2010

In electronic form on the EUR-Lex website under document number 32016M7818

UBS Discretionary Portfolio Management Service Working to protect, conserve and maximise your wealth. You and us.

Content. MUTUAL FUNDS MONTHLY REVIEW 2013 June. New Europe TOP20 Subfund 1. Russia TOP20 Subfund 2. Global Flexible Subfund 3

Survey of Reporting on Corporate Social Responsibility (CSR) by the Largest Listed Companies in 11 Central and Eastern European (CEE) Countries

One Bank for Corporates in Europe

FDI in Central, East and Southeast Europe: Declines due to Disinvestment

Content. MUTUAL FUNDS MONTHLY REVIEW 2012 June. New Europe TOP20 Subfund 1. Russia TOP20 Subfund 2. Global Flexible Subfund 3

IMS Retail Drug Monitor

New Europe TOP20 Subfund 1. Russia TOP20 Subfund 2. Global Flexible Subfund 3. Emerging Europe Bond Subfund 4. World Equity Subfund of Funds 5

Q TRADING STATEMENT

Press Presentation Q4 18 & FY18

BlackRock Emerging Europe plc

Oriola KD Corporation. Carnegie Lunch Seminar Helsinki, 11 May 2012

Net Sales: 1,107.6m, -5.4% vs. H of which -1.4% organic growth (1)

EFET Standard Contracts for Trading across Europe

Central and Eastern Europe Atlas* for the Retail and Consumer Sector

June 3 rd 2015, Koprivnica, Croatia. Podravka Inc. General Assembly

Content. MUTUAL FUNDS MONTHLY REVIEW 2013 December. New Europe TOP20 Subfund 1. Russia TOP20 Subfund 2. Global Flexible Subfund 3

WE ARE MORE THAN JUST ONE OPTION RUSSIAN MEDIA GROUP Presentation

Yandex Announces Third Quarter 2018 Financial Results

Hürriyet Investor Presentation. July 2007

Financial Results Q4 2012

Content. MUTUAL FUNDS MONTHLY REVIEW 2013 February. New Europe TOP20 Subfund 1. Russia TOP20 Subfund 2. Global Flexible Subfund 3

Yandex Announces First Quarter 2014 Financial Results

Guide to The Notification System for Exempt Medicinal Products

YANDEX N.V. FORM 6-K. (Report of Foreign Issuer) Filed 07/29/14 for the Period Ending 07/29/14

Yandex Announces Third Quarter 2017 Financial Results

moscow office Latitude n 55 45' 2.99" Longitude E "

Agenda. EFPIA Disclosure Rules - Basics Latest Developments in Transcription As of 1/15/14

Equity Funds Portfolio Update. Data as of June 2012

Behind the balance sheet: unlocking hidden value in credit. American Express Special Report

EBRD supporting cross-border activities of Czech companies

II. ESTONIAN BALANCE OF PAYMENTS FOR 2001

The Use of Pharmacoeconomic Principles in Local Drug Policy Decisions in Poland

Card Protection Metrics: Consumer Approaches to Card Protection Insurance in Europe

Q FINANCIAL RESULTS PRESENTATION Oslo, 12 May 2010

INTERIM RESULTS FOR THE SIX MONTHS ENDED 28 FEBRUARY 2015

REAL ESTATE CAPABILITY STATEMENT

Belarus slide package for a foreign investor

Growth (constant FX) Statutory Results Total Revenue $7.6 billion -0.2% -2.5% EBITDA $272.4 million +16.2% +13.6%

FLASH NOTE EQUITY RESEARCH. OUTPERFORM Price target 6.40 Price Elanix Biotechnologies AG (ELN-DE) Updates from webcast include financial outlook

by Intelace Research November 2010 Version: 10.01

The contents of this document must be taken into account by all individuals or entities that may have to make decisions or draw up or

Agile Investment Servicing. Service portfolio

Transcription:

Russia, Ukraine and Kazakhstan. Comparative analysis and development forecasts for 2015-2020

2 Language: English Date of publication: Delivery: pdf Price from: 2000 October 2015 Find out Which market is most receptive to OTC manufacturing and sales? What are top manufacturers planning in terms of expansion? Which CIS country offers the highest level of opportunity to new businesses? What is the structure of the OTC sector in the region and in each country? Which market is most highly saturated? Which OTC market has the highest current value? Click to buy

3 Informational highlights Consumer preferences for the purchase and use of OTC medicines & dietary supplements Regional market values and OTC market values for Russia and Ukraine Earnings and reach of primary OTC manufacturers in the region The regulatory landscape of the OTC market in CIS countries Profiles of market leading manufacturers of OTC products Advertising outlays of market leading companies Epidemiological data and trends Click to buy

4 Major advantages Comparative analysis Market forecasts Corporate profiles It describes the market in terms of value and structure, distribution channels and provides comparative analysis of the markets in each country. The document also features historical OTC market data that defines recent growth, along with detailed forecasts that reveal expected development over the next six years. This publication describes the top selling OTC products and identifies the leading manufacturers operating withing the analysed region. Click to buy

5 When to use it? Formulating a new sales plan Scanning the region for specific opportunities on the OTC market Performing competition research Launching a new OTC business or expanding an existing one. Who uses it? Management in the fields of OTC manufacturing and retail sales Wholesale pharmaceuticals distributors in CIS countries Non-pharmacy, chain and online sellers of OTC medicines and dietary supplements. Click to buy

6 Click here to buy this report Price list Language/Licence English Single 5 Users Country Global 2000 3000 4000 5000 Contact us to learn more about this report Request customised offer: trainings, research or consulting +48 12 618 90 00 request@pmrcorporate.com

Why do business professionals trust us? 7 As a London-based company, with operations abroad, we looked for the best-in-class Market Intelligence supplier. PMR brought us quality reports that improved our CEE market knowledge and understanding. We consider PMR a competent and professional company. PMR analysts understand our needs clearly and their services have fully met our expectations. I strongly recommend the company as a reliable partner in providing economic information and market analysis. PMR Research in Poland provided us with an effective and well-executed solution in a tight timeframe. Their researchers were very responsive to our unique needs. We were very satisfied with the overall results.

PMR s unique business offer 8 PMR's expertise Market reports & portals Data analysis & forecasting Consulting & market research Conferences, trainings & workshops Clients' benefits Increasing revenues Optimising costs Entering new markets Monitoring markets & competition

Behind the scenes 9 1995 PMR is established 200 tailored projects annually 150 off-the-shelf publications per year 50 in-house professionals 30 information portals & periodicals 25 Central & Eastern Europe countries analysed tel.: fax: +48 12 618 90 08 e-mail: www.pmrpublications.com www.pmrconsulting.com www.research-pmr.com